Tau and Caspase 3 as Targets for Neuroprotection : Table 1

Table 1: Models of NAP protection against tau pathology or increased markers of apoptosis.

Models of tau pathology detecting protective effects when treated with NAP

(i) Transgenic ADNP heterozygous mouse [4]

(ii) Transgenic human double-mutant tau mouse [5]

(iii) Triple transgenic mice expressing the amyloid (Aβ) precursor protein APP(Swe), presenilin PS1 (M146V), and tau (P301L) [45, 46]

(iv) Mixed neuroglial primary cultures treated with Aβ (1–42, 2.5 μM) [3]

(v) Primary cultures of astrocytes [47]

Models of apoptosis detecting protective effects when treated with NAP

(i) A stroke model using spontaneously hypertensive rats which underwent permanent middle cerebral artery occlusion [48]

(ii) A rat model of diabetes (streptozocin toxicity) [7]

(iii) A rat model of epilepsy [49]

(iv) PC-12 cells exposed to H₂O₂ [50]

(v) Primary neuronal cultures subjected to ischemia/ reperfusion schedule of 3 h/3 h [39]